S&P 500   4,168.46 (+0.56%)
DOW   32,965.21 (+0.49%)
QQQ   322.76 (+0.31%)
AAPL   166.40 (+0.64%)
MSFT   284.10 (+0.42%)
META   168.10 (+0.59%)
GOOGL   118.47 (+0.85%)
AMZN   141.92 (+0.80%)
TSLA   880.00 (+1.79%)
NVDA   177.38 (-6.59%)
NIO   20.14 (-0.40%)
BABA   91.10 (-1.58%)
AMD   100.11 (-2.15%)
MU   62.16 (-0.48%)
T   18.43 (+0.44%)
CGC   2.70 (+0.00%)
GE   75.57 (+1.63%)
F   15.51 (+1.37%)
DIS   108.82 (+2.05%)
AMC   23.72 (+6.94%)
PYPL   96.50 (+1.24%)
PFE   49.23 (-0.08%)
NFLX   228.51 (+0.76%)
S&P 500   4,168.46 (+0.56%)
DOW   32,965.21 (+0.49%)
QQQ   322.76 (+0.31%)
AAPL   166.40 (+0.64%)
MSFT   284.10 (+0.42%)
META   168.10 (+0.59%)
GOOGL   118.47 (+0.85%)
AMZN   141.92 (+0.80%)
TSLA   880.00 (+1.79%)
NVDA   177.38 (-6.59%)
NIO   20.14 (-0.40%)
BABA   91.10 (-1.58%)
AMD   100.11 (-2.15%)
MU   62.16 (-0.48%)
T   18.43 (+0.44%)
CGC   2.70 (+0.00%)
GE   75.57 (+1.63%)
F   15.51 (+1.37%)
DIS   108.82 (+2.05%)
AMC   23.72 (+6.94%)
PYPL   96.50 (+1.24%)
PFE   49.23 (-0.08%)
NFLX   228.51 (+0.76%)
S&P 500   4,168.46 (+0.56%)
DOW   32,965.21 (+0.49%)
QQQ   322.76 (+0.31%)
AAPL   166.40 (+0.64%)
MSFT   284.10 (+0.42%)
META   168.10 (+0.59%)
GOOGL   118.47 (+0.85%)
AMZN   141.92 (+0.80%)
TSLA   880.00 (+1.79%)
NVDA   177.38 (-6.59%)
NIO   20.14 (-0.40%)
BABA   91.10 (-1.58%)
AMD   100.11 (-2.15%)
MU   62.16 (-0.48%)
T   18.43 (+0.44%)
CGC   2.70 (+0.00%)
GE   75.57 (+1.63%)
F   15.51 (+1.37%)
DIS   108.82 (+2.05%)
AMC   23.72 (+6.94%)
PYPL   96.50 (+1.24%)
PFE   49.23 (-0.08%)
NFLX   228.51 (+0.76%)
S&P 500   4,168.46 (+0.56%)
DOW   32,965.21 (+0.49%)
QQQ   322.76 (+0.31%)
AAPL   166.40 (+0.64%)
MSFT   284.10 (+0.42%)
META   168.10 (+0.59%)
GOOGL   118.47 (+0.85%)
AMZN   141.92 (+0.80%)
TSLA   880.00 (+1.79%)
NVDA   177.38 (-6.59%)
NIO   20.14 (-0.40%)
BABA   91.10 (-1.58%)
AMD   100.11 (-2.15%)
MU   62.16 (-0.48%)
T   18.43 (+0.44%)
CGC   2.70 (+0.00%)
GE   75.57 (+1.63%)
F   15.51 (+1.37%)
DIS   108.82 (+2.05%)
AMC   23.72 (+6.94%)
PYPL   96.50 (+1.24%)
PFE   49.23 (-0.08%)
NFLX   228.51 (+0.76%)

Quest Diagnostic Stock is Ready to Move Higher

Quest Diagnostic Stock is Ready to Move Higher Medical diagnostic lab company Quest Diagnostic (NYSE: DGX) stock has been performing relatively stronger than the benchmark indices down only (-20%) on the year. The Company was a benefactor of the pandemic processing COVID test results, but volumes are falling as COVID wanes amidst mass vaccinations and boosters. PCR testing accounted for nearly $600 million in revenues, down (-28%) with nearly 60% occurring during the Omicron surge. That portion of revenues are expected to decline into 2023. However, it’s direct-to-consumer (DTC) business doubled in the quarter. The well-known lab serves nearly half of all the hospitals and physicians in the U.S. Processing over 1.8 million medical tests daily has enabled the Company to gather massive amounts of robust patient data. The Company shares a duopoly in the space with rival LabCorp (NYSE: LH). Despite inflationary pressures and revenue slip, Quest is making a strong recovery and raised it fiscal full-year 2022 top and bottom line guidance. Prudent investors looking for a defensive healthcare play in an established duopoly can look for opportunistic pullbacks in shares of Quest Diagnostic.

Q1 Fiscal 2022 Earnings Release


On April 21, 2022, Quest released its fiscal first-quarter 2022 results for the quarter ending March 2022. The Company reported an adjusted earnings-per-share (EPS) profit of $3.22 excluding non-recurring items versus consensus analyst estimates for a profit of $3.00, beating estimates by $0.22. Revenues fell (-4%) year-over-year (YOY) to $2.61 billion, missing analyst estimates for $2.64 billion. Quest CEO Steve Rusckowski commented, "COVID-19 volumes remained strong early in the quarter and decreased in February and March, in line with the market. We continue to make investments to further accelerate growth in the base business, while our efforts to improve productivity are helping us to offset inflationary pressures. Based on our strong performance in the quarter and our expectations for the remainder of 2022 we have raised our full year guidance."    

Raised Guidance

Quest issued fiscal full-year EPS guidance between $9.00 to $9.50 versus $8.98 consensus analyst estimates and previous guidance range of $8.65 to $9.35. Revenues are expected between $9.2 billion to $9.5 billion versus $9.35 billion consensus analyst estimates and prior guidance between $9 billion to $9.5 billion.

Conference Call Takeaways

CEO Rusckowski talked up the recovery on the $2.6 billion in total revenues. Due to the COVID emergency extension into July, the Company raised its COVID revenue guidance to come in between $850 million to $1 billion. The Company continues to make inroads with its overall base business with health plans and gaining market share. Health plans revenues grew faster than its overall base business in the quarter with deepening relationships through value based contracting. Nearly 30% of its health plans tie performance and reimbursement to value based elements like patient health quality, outcomes, and shares savings. He sees this growing to 50% in the coming years. He added, “We continue to make investments to accelerate growth in oncology, hematology, hereditary genetics, genomic sequencing services, and power services. Since we’ve ramped up our investments, and our advanced diagnostics portfolio, we have already accelerated growth by several 100 basis points and expect to deliver the 8% growth earlier than 2024, which we committed to at our 2021 Investor Day.”

Quest Diagnostic Stock is Ready to Move Higher

DGX Opportunistic Pullback Levels

Using the rifle charts on the weekly and daily time frames provides a precision view of the landscape for DGX stock. The weekly rifle chart peaked near the $146.03 Fibonacci (fib) level before selling back down to bottom off the $125.67 fib. The weekly rifle chart has been chopping flat but is attempting a breakdown as the weekly 5-period MA at $136.90 crosses down through the 15-period MA at 137.73. The weekly lower Bollinger Bands (BBs) sit near the $125.67 fib level. The weekly 50-period MA sits at $144.26. The weekly stochastic crossed down through the 60-band. The weekly market structure low (MSL) buy triggers on the $138.15 breakout. The daily rifle chart downtrend is slowing down as the 5-period MA flattens at $128.45 with a 15-period MA falling at $134.50 and 50-period MA at $136.40. The daily lower BBs sit at $122.20. The daily 200-period MA sits at $144.03 and upper daily BBs sit at $149.87. The daily stochastic crossed up with a mini pup towards the 20-band. Prudent investors can watch for opportunistic pullback levels at the $125.67 fib, $121.55 fib, $118.14 fib, $115.60 level, $112.46 fib, and the $108.44 fib level. Upside trajectories range from the $146.03 fib level up towards the $164.22 fib level.  

 

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Quest Diagnostics (DGX)
2.2379 of 5 stars
$139.38+1.0%1.89%11.60Hold$150.33
Compare These Stocks  Add These Stocks to My Watchlist 

Should you invest $1,000 in Quest Diagnostics right now?

Before you consider Quest Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.

While Quest Diagnostics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Free Email Newsletter

Complete the form below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter:

Most Read This Week

Recent Articles

Search Headlines:

Latest PodcastFind Investing Opportunities For The Rest of 2022

Today, Kate’s guest is Rhys Williams, chief investment officer for the Opportunistic All Cap Equity, a long-short strategy at Spouting Rock Asset Management.

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.